BRIEF published on 11/04/2024 at 20:10, 16 days 22 hours ago Evolution of the number of shares and voting rights of Poxel in 2024 Share Capital Voting Rights Actions AMF Biopharmaceutical
BRIEF published on 10/11/2024 at 07:35, 1 month 10 days ago Poxel Releases 2023 Universal Registration Document Corporate Governance Annual Financial Report CSR Report Poxel 2023 Registration Document
PRESS RELEASE published on 10/11/2024 at 07:30, 1 month 10 days ago Annual financial and audit reports / Terms of availability of the annual financial report Poxel announces availability of the 2023 Universal Registration Document including financial and governance reports, now filed with the AMF AMF Biopharmaceutical Company Financial Report Universal Registration Document Poxel
BRIEF published on 10/03/2024 at 18:35, 1 month 17 days ago Poxel announces its financial and strategic results for 2023 Financial Results Biopharmaceutical TWYMEEG® Poxel OrbiMed
BRIEF published on 09/30/2024 at 07:35, 1 month 21 days ago Poxel Secures $50M Non-Dilutive Financing from OrbiMed Non-dilutive Financing TWYMEEG® Poxel Royalty Monetization OrbiMed
PRESS RELEASE published on 09/30/2024 at 07:30, 1 month 21 days ago Inside Information / Other news releases Poxel monetizes TWYMEEG® royalties in a USD 50 million deal with OrbiMed. Proceeds to reduce debt and support rare disease activities. Webinars scheduled for investor updates Webinars Royalties TWYMEEG® Poxel OrbiMed
BRIEF published on 09/09/2024 at 07:35, 2 months 12 days ago POXEL announces a significant increase in its sales in the second quarter of 2024 Sales Treasury Partnerships TWYMEEG® Poxel
BRIEF published on 08/16/2024 at 08:16, 3 months 5 days ago Poxel: Evolution of the Share Capital and the Number of Voting Rights Share Capital Voting Rights Actions AMF Poxel
BRIEF published on 08/07/2024 at 08:05, 3 months 14 days ago Sumitomo Pharma and Poxel Unveil Study Results of TWYMEEG® for Type 2 Diabetes TWYMEEG® Poxel Sumitomo Pharma Type 2 Diabetes Renal Failure
PRESS RELEASE published on 08/07/2024 at 08:00, 3 months 14 days ago Inside Information / Other news releases Sumitomo Pharma and Poxel announce topline results from post-marketing clinical study on TWYMEEG(R) for Type 2 Diabetes treatment in Japan. Safety, tolerability confirmed in renal impairment patients Japan Poxel Sumitomo Pharma Type 2 Diabetes TWYMEEG
Published on 11/21/2024 at 17:35, 36 minutes ago 1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 41 minutes ago SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 1 hour 41 minutes ago The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 2 hours 10 minutes ago Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 2 hours 11 minutes ago Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 17:51, 20 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 20 minutes ago 2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 15:41, 2 hours 30 minutes ago Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 06:58, 11 hours 13 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 22 hours 51 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 10 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
